PMID- 35313416
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2303-9027 (Print)
IS  - 2226-7190 (Electronic)
IS  - 2226-7190 (Linking)
VI  - 11
IP  - 3
DP  - 2022 May-Jun
TI  - EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine 
      tumors: A systematic review and meta-analysis.
PG  - 170-185
LID - 10.4103/EUS-D-21-00044 [doi]
AB  - EUS-guided radiofrequency ablation (RFA) and ethanol ablation (EA) for pancreatic 
      neuroendocrine tumors (PNETs) have recently been reported with good outcomes. We 
      performed a systematic review and meta-analysis to evaluate the comparative 
      effectiveness and safety of EUS-RFA and EUS-EA in the treatment of PNETs. A 
      comprehensive search of multiple databases (through October 2020) was performed 
      to identify studies that reported outcomes of EUS-RFA and EUS-EA of PNETs. 
      Outcomes assessed included clinical success, technical success, and adverse 
      events (AEs). A total of 181 (100 EUS-RFA, 81 EUS-EA) patients (60.7 +/- 9.2 years) 
      with 204 (113 EUS-RFA, 91 EUS-EA) PNETs (mean size 15.1 +/- 4.7 mm) were included 
      from 20 studies. There was no significant difference in the rates of technical 
      success (94.4% [95% confidence interval (CI): 88.5-97.3, I(2) = 0] vs. 96.7% [95% 
      CI: 90.8-98.8, I(2) = 0]; P = 0.42), clinical success (85.2% (95% CI: 75.9-91.4, 
      I(2) = 0) vs. 82.2% [95% CI: 68.2-90.8, I(2) = 10.1]; P = 0.65), and AEs (14.1% 
      [95% CI: 7.1-26.3, I(2) = 0] vs. 11.5% [95% CI: 4.7-25.4, I(2) = 63.5]; P = 0.7) 
      between EUS-RFA and EUS-EA, respectively. The most common AE was pancreatitis 
      with the rate of 7.8% and 7.6% (P = 0.95) for EUS-RFA and EUS-EA, respectively. 
      On meta-regression, the location of PNETs in head/neck of pancreas (P = 0.03) was 
      a positive predictor of clinical success for EUS-RFA. EUS-RFA and EUS-EA have 
      similar effectiveness and safety for PNETs ablation. Head/neck location of PNETs 
      was a positive predictor for clinical success after EUS-RFA.
FAU - Garg, Rajat
AU  - Garg R
AD  - Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 
      Cleveland, Ohio, USA.
FAU - Mohammed, Abdul
AU  - Mohammed A
AD  - Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 
      Cleveland, Ohio, USA.
FAU - Singh, Amandeep
AU  - Singh A
AD  - Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 
      Cleveland, Ohio, USA.
FAU - Harnegie, Mary P
AU  - Harnegie MP
AD  - Cleveland Clinic Alumni Library, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Rustagi, Tarun
AU  - Rustagi T
AD  - Department of Gastroenterology and Hepatology, University of New Mexico, 
      Albuquerque, New Mexico, USA.
FAU - Stevens, Tyler
AU  - Stevens T
AD  - Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 
      Cleveland, Ohio, USA.
FAU - Chahal, Prabhleen
AU  - Chahal P
AD  - Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, 
      Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Endosc Ultrasound
JT  - Endoscopic ultrasound
JID - 101622292
PMC - PMC9258014
OTO - NOTNLM
OT  - EUS
OT  - ethanol
OT  - neuroendocrine tumor
OT  - pancreas
OT  - radiofrequency ablation
COIS- None
EDAT- 2022/03/23 06:00
MHDA- 2022/03/23 06:01
PMCR- 2022/03/21
CRDT- 2022/03/22 01:56
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/03/23 06:01 [medline]
PHST- 2022/03/22 01:56 [entrez]
PHST- 2022/03/21 00:00 [pmc-release]
AID - 340247 [pii]
AID - EUS-11-170 [pii]
AID - 10.4103/EUS-D-21-00044 [doi]
PST - ppublish
SO  - Endosc Ultrasound. 2022 May-Jun;11(3):170-185. doi: 10.4103/EUS-D-21-00044.